The CUI was created ( via expert input ) by weighing the relative benefit/risk of four components ( glycosylated hemoglobin -LSB- HbA@c -RSB- , percentage of patients with HbA@c @ % , hypoglycemia rate , and time to steady-state dose ) ; individual utility values were multiplied to compute CUI values for LY@ and LY@ relative to GL , and bootstrap samples were used to determine variability .